- 2020’s
- 2010’s
- 2000’s
- 1990’s
- 2020
-
-
09
Establishment of Helixmith Subsidiaries - Neuromyon, Cartexell.
-
07
VM202-CMT(Charcot-Marie-Tooth disease treatment) phase 1/2a initiated in Korea.
-
06
VM202-DPN(Diabetic neuropathy treatment)-Second Phase 3 initiated in U.S.
-
05
Experimental animal facility opened.
-
04
President Yoo Seung-shin Appointed as CEO - Kim Sun-young
& Yoo Seung-shin became Individual Representatives.
-
09
- 2019
-
-
11
Moved headquarters to new Magok Building, Seoul.
-
07
VM202-CLI(Critical Limb Ischemia), initiated phase 3 clinical trials in China
(Beijing Northland Biotech) -
04
Changed name to Helixmith.
-
11
- 2018
-
-
08
Kim Sun-young, became a sole representative as CEO.
-
07
Established Genopis Inc., contract manufacturing organization.
-
05
VM2020 designated as a Regenerative Medicine Advanced Theraphy
(RMAT) by the FDA for treatment of DPN
-
08
- 2017
-
-
04
VM507, Selected as Government Support Research Projects
VM202-PAD(Peripheral Artery Disease), approved in phase 3 clinical trials in China.
-
04
- 2016
-
-
09
VM202-ALS (Amyotrophic Lateral Sclerosis), Phase 1/2 clinical trials in US.
-
08
VM202-CAD(Coronary Artery Disease) Launches Phase 2 in Korea.
-
05
VM202-ALS(Amyotrophic Lateral Sclerosis), U.S. FDA fast track designation.
-
09
- 2015
-
-
12
Technology transfer contract signed by U.S. company Bluebird Bio for CAR-T treatment.
-
08
VM202-PAD(Peripheral Artery Disease), initiated phase 3 clinical trials in U.S.
-
04
VM202-DPN(Diabetic Peripheral Neuropathy), initiated phase 3-1 clinical trials in U.S.(VMDN-003)
-
12
- 2014
-
-
05
VM202-CAD(Coronary Artery Disease) for ischemic heart disease,
signed a development catheter supply contract.
VM202-ALS(Amyotrophic Lateral Sclerosis), Selected as the Ministry of
Health and Welfare's Advanced Medical Technology Development Project. -
02
VM202-ALS(Amyotrophic Lateral Sclerosis), Received orphan drug desingation from FDA
Gongshinbogam®(Health functional food for memory improvement) to be released.
-
05
- 2013
-
-
12
VM202-ALS(Amyotrophic Lateral Sclerosis) Joint development contract with Reyon Pharmaceuticals Co.Ltd.
-
10
VM202-ALS(Amyotrophic Lateral Sclerosis), Initiated Phase 1/2 clinical trial in U.S.
-
01
Muppin® (Health functional foods to improve articulation and cartilage health) released.
-
12
- 2012
-
-
12
LAYLA TAB™(Anthritis Treatment) relaeased in Korean market
VM202-DPN(Diabetic Neuropathy Treatment), Healthcare R&D Project Selection. -
07
Transferred technology for chronic hepatitis type B vaccines to Reyon Pharmaceutical Co., Ltd.
-
03
VM202-DPN(Diabetic Neuropathy Treatment), initiated phase 2 clinical trials in Korea
VM501(Thrombocytopenia Treatment) initiated Phase 3 clinical trials in China
PG201(Osteoarthritis) Korea's 7th Natural Products New Drug License.
-
12
- 2011
-
-
12
VM505 (antibody anticancer treatment) Joint development agreement with Pharmaceuticals Co., Ltd.
-
11
VM202-DPN(Diabetic Neuropathy Treatment) Initiated Phase 2 clinical trial (VMDN-002) in the U.S.
-
09
PG201(Osteoarthritis), applied for patent authorization in Korea
VM202-PAD(Peripheral Artery Disease) Initiates Phase II of Clinical Practice. -
02
VM206RY initiated clinical trial phase 1 in Korea
-
01
2011 Alex i™ (health functional food for relieving immune hypersensitivity) released in Korean market
-
12
- 2010
-
-
10
VM202-PAD(Peripheral Artery Disease)initiated clinical trials phase 2 in Korea.
-
07
Kim Yong-soo, became a sole representative as CEO.
-
10
- 2009
-
-
11
Alex® (health functional food for relieving immune hypersensitivity) and Ato Latte® (moisturizer) released
Heliccer Acquisition and Acquisition, Health Functional Food and New Natural
Products Pipeline secured. -
07
VM202-PAD (Ischemic retarded disease treatment), initiated phase 2
clinical trials in U.S.
Kim Sun-young and Kim Yong-soo became Individual Representatives. -
03
VM202-CAD (Healthy Heart Disease Therapy), initiated clinical trial
phase 1/2 in U.S.
VM202-DPN (Diabetic Neuropathy Therapy),initiated clinical trial
phase 1/2 in U.S.
PG102(Improvement of immune hypersensitivity), obtained individual
certification from the Ministry of Food and Drug Safety
-
11
- 2008
-
-
10
Selected as BioStar Project by Ministry of Knowledge Economy
-
07
Signed an MOU with Cobra Biologics, UK.
-
06
VM202-PAD(Peripheral Artery Disease) initiated clinical trial phase 1 in China.
-
01
VM206(anticancer gene therapy vaccine), technology transfer to Reyon Pharmaceutical Co., Ltd.
-
10
- 2007
-
-
11
Signed a contract with Korea Institute of Biotechnology to introduce targeted cancer treatment
technology. -
10
Signed a contract with Yonsei University to introduce selective tumor killing adenovirus technology.
-
01
VM106(Chronic Granulomatous Disease Therapy) initiated clinical trials phase I/II in Korea.
-
11
- 2006
-
-
11
VM202-CAD(Coronary Artery Disease) initiated clinical trial phase 1 in U.S.
-
10
VM202RY(Ischemic Coronary Artery Disease) initiated clinical trial phase 1 in Korea.
-
09
Exclusive Sales Agreement with Takara Bio, Japan.
-
01
VM106(Chronic Granulomatous Disease Therapy), joint development of Yuhan Corp.
Forming a Strategic Solidarity Agreement with Japan's Takara Bio Company
-
11
- 2005
-
-
12
Listed on the KOSDAQ
-
06
VM501 (Thrombocytopenia Treatment), technology transfer to GC Pharma.
-
05
Technology Transfer of Retroviral Vector to Takara Bio, Japan.
-
12
- 2004
-
-
12
Signed a Joint Research Agreement with Yuhan Corporation.
-
07
Signed Cross licensing agreement with Beijing Northland, China.
-
01
VMDA-3601(Icshemic foot disease treatment), initiated clinical trials phase 2 in Korea
VM202RY (Heptic coronary artery disease treatment),
technology transfer to Reyon Pharmaceutical Co., Ltd.
-
12
- 2003
-
-
02
Initiated consignment manufacturing of recombinant retrovirus
-
02
- 2001
-
-
02
VMDA-3601(Icshemic foot disease treatment), initiated clinical trial phase 1 in Korea.
-
02
- 2000
-
-
04
Investment of $6 Million from Takara Shuzo, Japan.
-
04
- 1999
-
-
10
Establishment of joint venture VioTech Ltd with Oxford Biomedica, UK
-
09
Company renamed to Viromed.
-
10
- 1998
-
-
09
Seoul Regional Small and Medium Business
Administration's certification of venture businesses. -
05
Export of Retroviral Vector to Takara Shuzo, Japan
-
09
- 1997
-
-
03
Technology Export to Oxford Biomedica, UK
-
01
Enactment of Green Cross Service Research Agreement
-
03
- 1996
-
-
11.21
Established as Byromedica Pacific Co., Ltd.
-
11.21